ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

ROS and miRNA signaling in ovarian cancer angiogenesis, tumor growth and treatment resistance

Joint Event on 15th International Congress on American Pathology and Oncology Research & International Conference on Microbial Genetics and Molecular Microbiology

Ling-Zhi Liu

Uinversity of Iowa, USA

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C5-057

Abstract
Ovarian cancer represents the fifth leading cause of cancer-related death among women. However, the mechanisms of ovarian cancer development and the treatment resistance remain to be elucidated. We found that ovarian cancer cells generate higher levels of reactive oxygen species (ROS) through NOX4 overexpression compared to immortalized normal ovarian epithelial cells, which are involved in inducing tumor growth and angiogenesis. More interestingly, ROS inhibit miR- 199a and miR-125b expression through increasing the promoter methylation of the miR-199a and miR-125b genes by DNA methyltransferase 1, thus increasing their targets HER2 or/and HER3 expression in ovarian cancer cells to regulate tumor angiogenesis. Cisplatin is commonly used in ovarian cancer treatment by inducing apoptosis in cancer cells as a result of lethal DNA damage. The cytoprotective functions of autophagy in cancer cells have been suggested as a potential mechanism for chemoresistance. We also demonstrated miR-152 as a new autophagy-regulating miRNA that plays a role in cisplatin resistance. MiR-152 expression was dramatically downregulated in the cisplatin-resistant cell lines and in ovarian cancer tissues associated with cisplatin resistance. Overexpression of miR-152 sensitized cisplatin-resistant ovarian cancer cells by reducing cisplatin-induced autophagy, enhancing cisplatin-induced apoptosis and inhibition of tumor growth through its direct target ATG14. Collectively, these data provide insights into novel mechanisms for ROS and miRNAs signaling in ovarian cancer angiogenesis, tumor growth, and treatment resistance.
Biography

Ling-Zhi Liu has completed her MD, PhD in 2000 from China Medical University. She is an Associate Professor in the Department of Pathology, University of Iowa. She has published more than 50 papers in high profiled journals and has been serving as an Editorial Board Member and Ad-hoc reviewers of several journals.

E-mail: ling-zhi-liu@uiowa.edu

 

Top